Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operationsand Financial Condition.
On August 2, 2017, Momenta Pharmaceuticals,Inc., a Delaware corporation (“Momenta”), announced its financial results for the quarter ended June 30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit99.1 to this Current Report on Form8-K.
The information in this Current Report on Form8-K (including Exhibit99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of Momenta under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
99.1Press Release issued by Momenta Pharmaceuticals,Inc. on August 2, 2017.
MOMENTA PHARMACEUTICALS INC ExhibitEX-99.1 2 exh9912q2017earningsrelease.htm EXHIBIT 99.1 Exhibit Exhibit 99.1MOMENTA PHARMACEUTICALS,…To view the full exhibit click here
About Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA)
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.
